Home > Transfusion-Dependent β-Thalassemia > Efficacy > Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms)

Total Body Iron Chelation in Patients With Mild to Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms)

EXJADE improved cardiac iron burden as measured by myocardial T2* in patients who were switched from other chelators

T2* Improvements Above the Normal Cardiac Iron Threshold in Patients With Mild-Moderate Cardiac Iron Levels
Prevention Threshold Chart

Three-year results of the EPIC cardiac substudy myocardial siderosis (N=101). The investigators assessed the efficacy and safety of EXJADE in removing myocardial iron in heavily transfused patients with β-thalassemia

  • T2* threshold of 20 ms was crossed by 2 years
  • 68% of patients with mild-moderate cardiac iron severity achieved normal cardiac iron levels (T2* ≥20 ms)

EXJADE provides serum ferritin and liver iron concentration reductions early that continue with treatment

Three-year data from the EPIC cardiac substudy showed continuous reductions in serum ferritin and liver iron concentration levels.

Continued LIC and Serum Ferritin Reductions Over 3 Years (n=47)
Continued LIC & Serum Ferritin Reductions Over 3 Years

Learn more about the cardiac substudy of the EPIC clinical trial.